Home · Science · Sep 9 archive
Study into career shocks finds what doesn't break expats makes them stronger
Confirmed
In Short: A study published in Science suggests that administering psilocybin before chemotherapy could prevent nerve damage, offering hope for cancer patients.
According to a study by researchers at the University of Texas MD Anderson Cancer Center, mice given psilocybin before chemotherapy were protected from nerve damage, a condition affecting about two-thirds of cancer patients. The protection lasted through six consecutive chemo sessions and persisted for eight months. Importantly, the psilocybin treatments had no impact on tumor growth or immune response, making them safe for even the sickest patients.
The study, published in the journal Science, found that lab mice given two doses of psilocybin before receiving chemotherapy were shielded from nerve damage. The protection held up through six consecutive chemo sessions and persisted for eight months, the study’s duration. Just as important, the psilocybin treatments, given as a pill, had no impact on tumor growth or immune response, making them safe for even the sickest patients.
What's still developing
- But we didn’t know whether global warming was making it stronger.
- This allowed them to ask how often a climate untouched by any human impact produces a swing this large on its own.
- Connection to reduced asthma or COPD flare-ups was stronger with higher doses of the drug, study found Connection to reduced asthma or COPD flare-ups was stronger with higher doses of the drug, study found Patients with asthma using the weight loss and diabetes drug semaglutide may experience fewer attacks, a new study suggests.
- “GLP-1 receptor agonists are widely used to treat type 2 diabetes and obesity. Previous research suggests that they may have anti-inflammatory effects and may improve lung-related outcomes, however, asthma and COPD outcomes have not been included as outcomes in GLP-1 drug trials,” said study lead Professor Chloe Bloom, clinical associate professor in respiratory epidemiology at the National Heart and Lung Institute at Imperial College London.
- The connection to reduced asthma or chronic obstructive pulmonary disease (COPD) flare-ups was stronger among those receiving higher doses of semaglutide.
- “We wanted to use real-world health records to investigate whether people with asthma or COPD who started GLP-1 receptor agonists had fewer acute respiratory attacks.” The study, presented to the European Respiratory Society Congress in Barcelona, Spain, examined whether a number of treatments were linked to a reduction in exacerbations.
- NBA commissioner Adam Silver sent memos to league stakeholders Friday, including the WNBA Board of Governors, informing them that leadership will “begin the process of selecting a new WNBA commissioner later this month,” a league source said.
- “Huntsville’s music network continues to grow stronger every year, and the 2026 music audit makes that clearer than ever,” Mayor Tommy Battle said.